• June 16-19, 2025
  • Boston Convention & Exhibition Center

Martin Gouldstone

Loading
Martin Gouldstone

Martin Gouldstone

Chief Executive Officer
Oncimmune
Martin brings 30 years corporate finance and business development experience in the CRO, healthcare and pharmaceutical sectors to his role as CEO at Onciumme. Most recently, Martin was a Global SVP Business Development at Owkin, where he managed the commercial teams in the USA and Europe and led new strategic research partnerships. Martin was Chief Business Officer at Sensyne Health where he drove growth with particular focus on expanding reach in the US market and Pharmaceutical sector; Global SVP at Syneos One and Head of Capital Solutions for Syneos Healthcare where he developed and led Capital Solutions service; Chief Business Officer at BenevolentAI where he was responsible for all commercial activities. He was previously a Partner at Results Healthcare, where he co-led the healthcare practice;Head of Lifesciences in the UK for BDO, the Lead for the M&A process in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant, Pharmacopeia, Sareum. He has extensive experience buying and selling multi-billion dollar deals across Europe and the US and negotiating multi-year research partnerships. Currently, Martin is a Non-Executive Board Director for Open Orphan Plc and sits on the Board of Trustees of Orthopaedic Research UK. He holds a BSc in Genetics.
Speaking In

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS